Emcure Pharmaceuticals Announces Strong Q2FY25 with 20% Revenue Growth and 38% Profit After Tax Growth
Revenue from operations at Rs 2,002Cr, up 20.4% YoY and 10.3% QoQ EBITDA margins at 20.8% with EBITDA up 26.1% YoY and 15.8% QoQ PAT at 202 Cr, up 38.2% YoY with PAT margins at 10.1% Domestic business sales at 933Cr, up 15.4% YoY International business sales at 1,069Cr, up 25.0% YoY Bengaluru, November 7, 2024: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its unaudited consolidated financial results for the quarter ended September 30th,